Presentation is loading. Please wait.

Presentation is loading. Please wait.

C3 Bio Confidential 16.04.2015 Combating diseases with small molecule compounds C3BIO GmbH C3BIO GmbH.

Similar presentations


Presentation on theme: "C3 Bio Confidential 16.04.2015 Combating diseases with small molecule compounds C3BIO GmbH C3BIO GmbH."— Presentation transcript:

1 C3 Bio Confidential 16.04.2015 Combating diseases with small molecule compounds C3BIO GmbH C3BIO GmbH

2 C3 Bio Confidential 16.04.2015 Company concept: rational drug design Patents and exclusive world licenses on families of compounds (purines and pyrazolopyrimidines) Patents and exclusive world licenses on families of compounds (purines and pyrazolopyrimidines) Extensive network of cooperation partners Extensive network of cooperation partners Progress made in 3 indication areas: Rheumatoid arthritis, restenosis and cancer Progress made in 3 indication areas: Rheumatoid arthritis, restenosis and cancer

3 C3 Bio Confidential 16.04.2015 Pyrazolopyrimidines Roscovitine Roscovitine

4 C3 Bio Cancer Recognized hallmarks of cancers Recognized hallmarks of cancers  Uncontrolled proliferation  Evasion of apoptosis  Sustained angiogenesis  Genomic instability Common target: cyclin-dependent kinases (CDKs) Common target: cyclin-dependent kinases (CDKs) Confidential 16.04.2015

5 C3 Bio Cancer Identified compounds have increased: Identified compounds have increased:  Activity in biochemical and cellular assays  Potency in vivo  Metabolic stability Tumour cell migration as well as endothelial migration are specifically being investigated to prevent cancer metastasis-a number of compounds show promising results Tumour cell migration as well as endothelial migration are specifically being investigated to prevent cancer metastasis-a number of compounds show promising results Confidential 16.04.2015

6 C3 Bio Confidential 16.04.2015 Restenosis Focus is on identification of new drug candidates interfering with vascular smooth muscle cells (VSMC) proliferation Focus is on identification of new drug candidates interfering with vascular smooth muscle cells (VSMC) proliferation Identified compounds may be useful for anti- restenotic therapy-some of the work is published Identified compounds may be useful for anti- restenotic therapy-some of the work is published

7 C3 Bio Confidential 16.04.2015 Rheumatoid Arthritis Concentrate on the 30-40% non- responding RA patients Concentrate on the 30-40% non- responding RA patients New targets-neutrophils and synovial fibroblasts New targets-neutrophils and synovial fibroblasts Patients at early stage of disease progression Patients at early stage of disease progression

8 C3 Bio Confidential 16.04.2015 Rheumatoid Arthritis: LGR1407 induces neutrophil apoptosis

9 C3 Bio Confidential 16.04.2015 Rheumatoid Arthritis: LGR1407 inhibits TNF-induced secretion of IL-8 in neutrophils Rheumatoid Arthritis: LGR1407 inhibits TNF-induced secretion of IL-8 in neutrophils

10 C3 Bio Confidential 16.04.2015 Rheumatoid Arthritis: LGR1407 inhibits proliferation of synovial fibroblasts from RA patients

11 C3 Bio 16.04.2015 Rheumatoid Arthritis Rheumatoid Arthritis Molecular target had been identified Molecular target had been identified Compounds are orally available Compounds are orally available Toxicology and pharmacokinetic studies indicate a useful therapeutic window Toxicology and pharmacokinetic studies indicate a useful therapeutic window in vivo studies successfully carried out in vivo studies successfully carried out

12 C3 Bio Confidential 16.04.2015 Combating diseases with small molecule compounds For more information contact For more information contact Dr. Paul Pechan, CEO Dr. Paul Pechan, CEO Email:ppechan@compuserve.com Email:ppechan@compuserve.com Tel: 49 89 67847951 Tel: 49 89 67847951


Download ppt "C3 Bio Confidential 16.04.2015 Combating diseases with small molecule compounds C3BIO GmbH C3BIO GmbH."

Similar presentations


Ads by Google